Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment-experienced people news

Show

From To
Higher pill burden is associated with poorer adherence to HIV therapy and reduced chances of achieving an undetectable viral load

Lower pill burden is associated with higher rates of adherence to HIV treatment and better virological outcomes, according to the results of a meta-analysis published in the online

Published
31 January 2014
By
Michael Carter
Janssen to Stop Offering "Virtual Phenotype" Testing, and Musings on Progress

As is plainly obvious to anyone doing HIV care, the incidence of new patients with the sort of HIV drug resistance for which the test was developed has plummeted. There simply aren't many new patients out there who have multiple mutations, especially in the PI-drug class, and who will need the computational black-box firepower provided by a vircoTYPE.

Published
27 November 2013
From
The BodyPRO
Second- and Third-Line ART Cost 24% and 41% More Than First Line in US

Second-line antiretroviral therapy (ART) costs 24% more per year than first-line therapy in the United States, and third-line therapy costs 41% more than first-line therapy, according to a large insurance claims-based analysis.

Published
17 September 2013
From
NATAP
No Dose Adjustment With Etravirine Plus ATV/r in Treatment Experienced: Randomized Trial

After 48 weeks of the randomized TEACH trial, virologic responses were equivalent when antiretroviral-experienced people took standard-dose etravirine with 300/100 or 400/100 mg of atazanavir/ritonavir daily.

Published
22 July 2013
From
NATAP
Third-line ARVs could widen treatment gap in Zimbabwe

HIV/AIDS activists in Zimbabwe have welcomed the government's move to address the problem of HIV drug resistance by introducing third-line antiretroviral drug (ARVs). But it remains unclear how the cash-strapped government will finance this, as procuring the drugs will invariably be expensive and could divert resources away from other HIV treatment efforts.

Published
12 March 2013
From
IRIN Plus News
New integrase inhibitor dolutegravir helps treatment-experienced people on failing therapy

The next-generation integrase inhibitor dolutegravir proved more beneficial than raltegravir (Isentress) for treatment-experienced people with resistance to two or more antiretroviral drug classes, researchers reported in a poster

Published
10 March 2013
By
Liz Highleyman
Can people with resistant HIV omit NRTIs when switching from a failing regimen?

Omitting nucleoside reverse transcriptase inhibitors (NRTIs) when switching from a non-suppressive regimen to a new combination with at least two active agents can reduce pill burden and

Published
07 March 2013
By
Liz Highleyman
Australian researchers project that many HIV-positive people will run out of treatment options

Running out of antiretroviral treatment options may severely curtail the life expectancy of people with HIV in resource-rich countries, according to Australian research published in

Published
22 January 2013
By
Michael Carter
Prevalence of drug-resistant HIV has fallen dramatically among antiretroviral-experienced patients in Western Europe

There has been a significant fall in the proportion of HIV-positive people in Western Europe with experience of HIV treatment who have resistance to antiretroviral

Published
22 January 2013
By
Michael Carter
Any reduction in viral load has immunologic benefits for people with HIV who have triple-class treatment failure

HIV therapy that achieves even modest reductions in viral load can have profound immunological benefits for people with triple-class treatment failure, European investigators report in the online edition

Published
08 January 2013
By
Michael Carter
← First12345...14Next →

Filter by country